Earnings Call Insights: Shoulder Innovations (SI) Q1 2026 Management View "I'm very pleased to report that 2026 is off to a strong start" and the company "deliver[ed] first quarter net revenue of $16.7 million, an increase of 65% year-over-year and 16% sequentially," with "first quarter gross margin" at "77.7%," according to (Executive chairman, CEO & president Robert Ball). (Executive chairman, C...
Earnings Call Insights: Shoulder Innovations (SI) Q1 2026 Management View "I'm very pleased to report that 2026 is off to a strong start" and the company "deliver[ed] first quarter net revenue of $16.7 million, an increase of 65% year-over-year and 16% sequentially," with "first quarter gross margin" at "77.7%," according to (Executive chairman, CEO & president Robert Ball). (Executive chairman, CEO & president Ball) said SI raised 2026 guidance because of "the strength of these results," "our growing scale" and "the efficiency of our commercial organization," adding: "we are raising our full year 2026 net revenue guidance today to a range of $65 million to $68 million" versus "our prior range of $62 million to $65 million." (Executive chairman, CEO & president Ball) reiterated three priorities: "driving adoption among new surgeons," "increasing penetration" to lift procedural volume, and "adding products to our portfolio," including "expanding indications and enabling technology." (Executive chairman, CEO & president Ball) highlighted commercial and education activity, including "44 total SI-sponsored educational events in first quarter" and an April national symposium where "surgeon attendance was up over 70% versus last year's event." He said among attendees not already core/contender customers, "more than 70% have already either performed their first case with our system, committed to their first case or committed to increasing volume." (Executive chairman, CEO & president Ball) reported procedure/volume signals: "total implant volume" rose "51% year-over-year to 2,184 units" and said "the standout signal is that our highest growth surgeon category in the first quarter was core, both year-over-year and sequentially." (Executive chairman, CEO & president Ball) detailed product milestones: SI moved its "InSet 135RFX Humeral Stem" from "limited user release to full commercial launch" after expanded FDA clearance, and said it also started a limited user release of "...
Earnings Call Insights: Worksport Ltd. (WKSP) Q1 2026 Management View "Q1 2026 was the investment and launch readiness quarter" and "Q2 2026 and the second half are about conversion" with focus on "Shipments, sales channel activation, margin efficiency improvement, and lower operational cash burn" (Founder, Chairman, President, CEO & Secretary Steven Rossi). "In January, the SOLIS and COR started ...
Earnings Call Insights: Worksport Ltd. (WKSP) Q1 2026 Management View "Q1 2026 was the investment and launch readiness quarter" and "Q2 2026 and the second half are about conversion" with focus on "Shipments, sales channel activation, margin efficiency improvement, and lower operational cash burn" (Founder, Chairman, President, CEO & Secretary Steven Rossi). "In January, the SOLIS and COR started commercial shipping" and "In April 2026, NEXUS launched commercially" alongside "distribution with Tri-State Enterprises, including their placement of an initial purchase order" (CEO Rossi). "Our fiscal 2025 Form 10-K included a going concern explanatory disclosure" and management said it is being addressed by "convert inventory into revenue, grow gross margins in each of our sales channels and reduce operating cash consumption" (CEO Rossi). "During Q1 of 2026, we raised approximately $2.2 million" and "issued 1.46 million shares of common stock" while stating, "Our strategy remains to use the ATM as a tactical tool" (CEO Rossi). "Net sales for Q1 2026 were $3.3 million" and "Gross margin for Q1 2026 was approximately $0.9 million" (CFO, Principal Financial Officer & Principal Accounting Officer Jennifer Kartychak). Outlook "We provided revenue 2026 guidance of $35 million to $42 million in our 2025 Form 10-K" and "hold off on specific guidance updates, but reaffirm our previous broader guidance" (CEO Rossi). "Accordingly, we plan to provide annual financial guidance early each calendar year" and "The primary driver for moving away from quarterly guidance updates is to increase our emphasis on allocation of resources on long-term strategy" (CEO Rossi). Compared with the prior call’s guidance language, management previously said, "For 2026, we expect revenue of $35 million to $42 million with gross margins of approximately 35%" and "We plan to update investors" (Founder, Chairman, President, CEO & Secretary Rossi, Q4 2025). Financial Results "Revenue grew approximately 48% y...